Christine Rauschkolb

Author

Johnson & Johnson (United States)

Also Known As

C Rauschkolb, C. Rauschkolb, Christine Rauschkolb, Christine Rauschkolb, MD, PhD, Klein, Michael

Publications

6.9K

Citations

H-Index

Concepts

All Affiliations

Johnson & Johnson (United States)Grünenthal Group (Germany)Pfizer (United States)University of Pennsylvania University of Rochester

About

Christine Rauschkolb is an author at Johnson & Johnson (United States) specializing in medicine, health sciences, and pain management.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	4.3K
2	Health Sciences	9	9	4.2K
3	Diabetes	1	1	24
4	Emergency Medicine	1	1	72
5	Gastroenterology	1	1	52

Christine Rauschkolb

Publications

5.4K

Citations

H-Index

Page 1

	Year	Citations
Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations Robert H. Dworkin, Dennis C. Turk, Kathleen W. Wyrwich, Journal of Pain Immpact RecommendationsPain ResearchPain TherapyInterventional Pain MedicineClinical Importance	2007	3.2K
Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations Dennis C. Turk, Robert H. Dworkin, Laurie B. Burke, Pain Immpact RecommendationsPain ResearchPain TherapyPerformance StudiesHealth Sciences	2006	298
Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations Robert H. Dworkin, Dennis C. Turk, Sarah Peirce‐Sandner, Pain Pain TherapyPain MedicinePharmacotherapyPain SyndromeClinical Trials	2012	276
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial Sherwyn Schwartz, Mila Etropolski, Douglas Y. Shapiro, Current Medical Research and Opinion	2010	256
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study Robert Buynak, Douglas Y. Shapiro, Akiko Okamoto, Expert Opinion on Pharmacotherapy	2010	250
Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee Marc Afilalo, Mila Etropolski, Brigitte Kuperwasser, Clinical Drug Investigation Pain TherapyHealth SciencesPain MedicinePostoperative Pain ManagementChronic Musculoskeletal Condition	2010	226
Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain James Wild, Stefan Grond, Brigitte Kuperwasser, Pain Practice	2010	181
A Randomized Withdrawal, Placebo-Controlled Study Evaluating the Efficacy and Tolerability of Tapentadol Extended Release in Patients With Chronic Painful Diabetic Peripheral Neuropathy Aaron I. Vinik, Douglas Y. Shapiro, Christine Rauschkolb, Diabetes Care	2014	135
Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study M. Hale, David Upmalis, Akiko Okamoto, Current Medical Research and Opinion	2009	132
A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain Stephen Daniels, Ed Casson, Jens‐Ulrich Stegmann, Current Medical Research and Opinion	2009	131

Page 1